J&J wants $100M-plus discount on Elan

It's back to the drawing board for Johnson & Johnson and Elan. In the wake of a judge's ruling in favor of Elan's Tysabri partner Biogen Idec, J&J is lobbying for a lower price for their $1.5 billion deal, Reuters reports. That $1.5 billion was to buy J&J an 18.4 percent stake in Elan, a majority position in Elan's pipeline of Alzheimer's drugs and--here's the sticking point--an option to finance a buyout of Biogen's Tysabri share if the opportunity arose.

Biogen and Elan's partnership deal has a change-in-control provision: If one of the companies is sold, the other can buy its share of Tysabri. But Elan isn't exactly flush with cash, and so it gave J&J the option to finance that purchase. If J&J were to cough up the money, it would get a 50 percent share of the multiple sclerosis drug. But earlier this month a judge ruled that the financing option breached Elan's partnership deal with Biogen. So, Elan and J&J have to come up with a different plan, or risk losing that half-stake in Tysabri.

According to the Wall Street Journal, J&J wants to cut the price accordingly--by at least $100 million off that $1 billion minority-stake purchase. (The $500 million price for the Alzheimer's alliance wouldn't change.) That could be a problem for Elan; as In Vivo notes, the company had intended to pay down long-term debt with the deal proceeds. Elan had $1.8 billion in debt at the end of the second quarter.

- read the WSJ news
- see the coverage from Reuters
- check out In Vivo's take

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.